Format

Send to

Choose Destination
Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18.

Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.

Author information

1
a Department of Respiratory Medicine, Graduate School of Medicine , Osaka City University , Osaka , Japan.
2
b Department of Respiratory Medicine , Aichi Medical University School of Medicine , Aichi , Japan.
3
c Clinical Research Center , National Hospital Organization Kinki-chuo Chest Medical Center , Osaka , Japan.

Abstract

INTRODUCTION:

While epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) lead to longer progression-free survival (PFS) when compared with conventional chemotherapy in non-small-cell lung cancer (NSCLC) harboring activating EGFR mutations, the role of EGFR-TKI remains unclear in EGFR-wild-type (WT) NSCLC.

AREAS COVERED:

This article reviews selected data from randomized trials regarding the use of TKIs in EGFR-WT NSCLC. Nine randomized phase III trials have compared EGFR-TKI with chemotherapy in NSCLC patients in a second or later line setting. Two of these trials, TAILOR and DELTA, which were designed to investigate treatment benefits according to EGFR genotype, demonstrated that docetaxel chemotherapy displayed significantly better in progression-free survival (PFS) when compared with the EGFR-TKI erlotinib. Biomarkers to predict clinical benefits of the drug against EGFR WT tumor, and the efficacy of combination regimens using erlotinib or single-use afatinib against tumors are also covered in this article.

EXPERT OPINION:

Considering the modest benefits of erlotinib for EGFR-WT tumors, future studies are warranted, including the exploration of useful biomarkers and new treatment strategies for EGFT-TKI use, as well as the development of more sensitive EGFR mutation tests.

KEYWORDS:

Chemotherapy; EGFR tyrosine kinase inhibitor; EGFR wild-type; non-small cell lung cancer; review

PMID:
26781399
DOI:
10.1517/14656566.2016.1109635
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center